Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silo Pharma, Inc. (Nasdaq: SILO) SEC filings page on Stock Titan provides direct access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Silo’s status as a developmental-stage biopharmaceutical and cryptocurrency treasury company, its capital structure, and its governance and compliance framework.
For investors analyzing Silo’s biopharmaceutical programs and digital assets strategy, key filings include current reports on Form 8-K, the Definitive Proxy Statement (DEF 14A), and registration statements such as Form S-1. Recent 8-Ks describe material events including the launch of a cryptocurrency advisory board, asset purchases related to crypto software and domains, Nasdaq minimum bid price notifications, strategic agreements with Fireblocks for digital asset custody, and securities purchase agreements for registered direct offerings and concurrent private placements.
The Form S-1 registration statement filed in October 2025 details the resale of shares issuable upon exercise of investor and placement agent warrants issued in a financing transaction, including warrant terms, exercise prices, and potential proceeds if exercised. This document helps readers understand how warrant exercises could affect Silo’s share count and capital resources.
Silo’s DEF 14A proxy statement outlines matters submitted to shareholders at the 2025 annual meeting, such as director elections, ratification of the independent registered public accounting firm, authorization of a reverse stock split within a specified range, and an amendment to increase shares reserved under the equity incentive plan. An 8-K reporting the voting results shows how shareholders acted on these proposals.
Additional 8-K filings cover topics such as an evaluation license and option agreement with the University of Maryland, Baltimore for intellectual property related to central nervous system-homing peptides and the establishment of a cryptocurrency advisory board with related equity compensation. Together, these documents provide a regulatory record of Silo’s efforts to advance its SPC-15 and SP-26 programs, manage listing compliance on the Nasdaq Capital Market, and implement its crypto treasury strategy.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can be used to quickly surface items related to financings, listing compliance, governance changes, and strategic agreements within Silo Pharma’s disclosure history.
Silo Pharma, Inc. is registering up to 5,023,340 shares of common stock underlying Series A-1 warrants, Series A-2 warrants and placement agent warrants.
The prospectus offers common stock purchase warrants exercisable upon issuance at an exercise price of $0.60 per share; Series A-1 warrants expire five years from the Initial Exercise Date and Series A-2 warrants expire eighteen months from the Initial Exercise Date. The offering price per common stock purchase warrant is $0.60. The company states it will receive proceeds only upon cash exercise of the warrants and may receive up to approximately $3.0 million if all warrants are exercised at the stated price. The company discloses Nasdaq minimum bid-price noncompliance and a second compliance period extending to June 22, 2026, and lists operating losses and cash balances in its historical consolidated financial data.
Silo Pharma, Inc. is registering up to 820,911 shares of common stock issuable upon the exercise of certain warrants.
The Shares consist of 763,638 shares issuable upon exercise of the July 2024 Investor Warrants at $2.75 per share and 57,273 shares issuable upon exercise of the July 2024 Placement Agent Warrants at $3.4375 per share. Upon cash exercise of all Warrants the company would receive aggregate gross proceeds of approximately $2.3 million. The registration covers resale by the Selling Shareholders; the company will not receive proceeds from resale transactions.
Shares outstanding would be 17,087,504 assuming full exercise of the Warrants; Nasdaq minimum-bid noncompliance and remediation periods are disclosed.
Silo Pharma, Inc. files a Post-Effective Amendment to its Form S-1 registering up to 5,023,340 shares of common stock underlying common stock purchase warrants and placement agent warrants.
The amendment re-states the offering of 2,416,670 Series A-1 warrants, 2,356,670 Series A-2 warrants and up to 250,000 placement agent warrants, each warrant tied to an underlying common share and priced at a public offering price of $0.60 per combined unit. The Company states it will receive proceeds only if warrants are exercised, estimated at approximately $3.0 million if all warrants are cashed in at the stated exercise price. The filing also incorporates the Company’s Form 10-K for the year ended December 31, 2025 and updates disclosure including Nasdaq minimum bid-price noncompliance and related cure period.
Silo Pharma, Inc. amends its Form S-1 to register for resale up to 820,911 shares of common stock issuable upon exercise of outstanding warrants. The registration covers (i) 763,638 shares from July 2024 investor warrants at an exercise price of $2.75 and (ii) 57,273 placement agent warrant shares at $3.4375. The company states it would receive up to approximately $2.3 million if all warrants are cash-exercised. The selling shareholders may sell from time to time; the company will not receive resale proceeds. Shares outstanding were reported as 17,087,504 assuming full exercise. The filing notes Nasdaq minimum bid-price noncompliance procedures with an extended compliance period through June 22, 2026.
Silo Pharma, Inc. entered into an asset purchase agreement to acquire the software for the QwikAgents web-based application and related domain names from Many Ads Inc. In exchange for these assets, Silo issued 2,100,000 shares of its common stock to the seller.
The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo for issues such as misrepresentations, software infringement, and specified misconduct. The shares were issued in a private, unregistered transaction relying on a securities law exemption.
Silo Pharma, Inc. filed its annual report describing a developmental-stage biopharmaceutical and cryptocurrency company focused on CNS and pain disorders. The pipeline includes SPC-15, an intranasal PTSD and anxiety treatment advancing toward an IND, SP-26 ketamine implants for fibromyalgia, SPC-14 for Alzheimer’s disease and SPU-16 for multiple sclerosis.
Silo licenses key IP from Columbia University, the University of Maryland, Baltimore and Medspray for nasal delivery technology, and reports five issued patents with 20 pending applications. In 2025 it added a cryptocurrency treasury strategy, holding crypto assets of $221,817 and staking $98,584 to earn yield.
The company highlights significant regulatory and clinical risks around psychedelic-based therapies, controlled substance compliance and financing needs. As of March 27, 2026, it had 14,166,593 common shares outstanding, three full-time employees and a Board-authorized stock repurchase program of up to $1 million through December 31, 2026.
Silo Pharma, Inc. reported two equity-related actions. The company issued 848,320 shares of common stock to its investor relations consultant as a $250,000 commitment fee, valued at $0.2947 per share, in connection with restarting a service agreement. The issuance is an unregistered transaction under Section 4(a)(2) of the Securities Act and provides no cash proceeds to the company.
The board of directors also approved a stock repurchase program authorizing the company to buy back up to $1 million of its common stock through open market or privately negotiated transactions. Silo Pharma had 13,318,273 shares outstanding as of November 13, 2025, providing context for the potential scale of repurchases.
Anson Funds-linked entities report a 4.9% stake in Silo Pharma, Inc. They collectively beneficially own 699,486 shares of Silo Pharma common stock, including shares underlying warrants, as of the reporting described for 12/31/2025.
Anson Funds Management LP and Anson Advisors Inc. act as co‑investment advisers to private funds that hold the shares, with related general partner and individual principals sharing voting and disposition power. The warrants include a 4.99% beneficial ownership limitation, which caps how much of the company can be owned through warrant exercise at any time. The securities are described as acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of Silo Pharma.